Science Is at the Core of What We Do
Backed by cutting-edge science and a compassionate mission to extend lives, our therapies offer patients real hope for a healthier, cancer-free future. Driven by values like integrity, empathy, and perseverance, CVBio is transforming treatment and redefining what’s possible.
Pediatric Clinical Trials
New Clinical Trials
A Phase1 trial was completed to evaluate the safety and efficacy of DNX-2401 in pediatric patients with Diffuse Intrinsic Pontine Glioma (DIPG). Patients who are less than 18 years old with newly diagnosed DIPG were eligible.
DNX-2401 has been granted Fast Track and Orphan designation by the FDA, Orphan and PRIME designation by the EMA, and Promising Innovative Medicine designation by the MHRA.
Adult Clinical Trials
New Clinical Studies
A Phase 1 trial was completed evaluating DNX-2401 as a monotherapy treatment for adults with recurrent glioblastoma (GBM). The full results of this study are published here [Lang 2018].
The Phase 2 CAPTIVE trial was conducted in collaboration with Merck to evaluate the efficacy and safety of DNX-2401 in combination with pembrolizumab (KEYTRUDA), Merck’s anti-PD-1 therapy. Adult subjects diagnosed with GBM or gliosarcoma who experienced disease progression after initial treatment were eligible.
The full results of this study are published here [Nassiri 2023].
DNX-2401 has been granted Fast Track and Orphan designation by the FDA, Orphan and PRIME designation by the EMA, and Promising Innovative Medicine designation by the MHRA.